Onkologie, Hämatologie - Daten und Informationen
SitemapSitemap  


Literaturreferenzen des Artikels "Erworbene hämolytische Anämien"

Autor/en: A. Salama
Letzte Änderung: 11.11.2003
  • Ahrens N, Heymann G, Meyer 0, Kiesewetter H, Salama A.
    Results of Treatment with Rituximab (Anti-CD20) in Three Patients with Autoimmune Hemolytic Anemia and/or Immune Thrombocytopenia and a Concise Review of Reported Cases.
    Infus Ther Transfus Med 2002;29:277-281.


  • Astori C, Bonfichi M, Pagnucco G, Bernasconi P, Lazzarino M, Orlandi E, Bernasconi C.
    Treatment with recombinant human erythropoietin (rHuEpo) in a patient with paroxysmal nocturnal haemoglobinuria: evaluation of membrane proteins CD55 and CD59 with cytofluorometric assay.
    Br J Haematol 1997;97(3): 586-588.


  • Beauregard P, Blajchman MA.
    Hemolytic and Pseudo-Hemolytic Transfusion Reactions: An Overview of the Hemolytic Transfusion Reactions and the Clinical Conditions That Mimic Them.
    Transfusion Medicine Reviews 1994;VIII/3:184-199.


  • Bessler M, Masin PJ, Hillmen P, Miyata T, Yamada N, Takeda J, Luzzatto L, Kinoshita T.
    Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene.
    The EMBO Journal 1994;13:110-117.


  • Beutler E.
    Hemolytic anemia due to infections with microorganisms.
    Fifth edition, Williams Hematology 1995;63:674-676.


  • Beutler E.
    Hemolytic anemia due to chemical and physical agents.
    Fifth edition, Williams Hematology 1995;62:670-673.


  • Bowman JM.
    Treatment Options for the Fetus With Alloimmune Hemolytic Disease.
    Transfusion Medicine Reviews 1990;IV/3:191-207.


  • Buchanan GR, Boxer LA, Nathan DG.
    The acute and transient nature of idiopathic immune hemolytic anemia in childhood.
    J Pediatrics 1976;88:780-783.


  • Chemnitz J, Draube A, Scheid C, et al.
    Sucessful Treatment of Severe Thrombotic Thrombocytopenic Purpura With the Monoclonal Antibody Rituximab.
    Am J Hematology 2002;71:105-180.


  • Dabrow MB, Gabuzda TG.
    Nonimmune Hemolysis and Toxic Methemoglobinemia.
    Comprehensive Toxicology.
    Elsevier Science Ltd., United Kingdom, 1997;4:55-72.


  • Dacie JV, Worlledge SM.
    Auto-Immune Hemolytic Anemias.
    Progr Hematol 1969;6:82-120.


  • Engelfriet CP, Overbeeke MAM, von dem Borne AEGKr.
    Autoimmune Hemolytic Anemia.
    Seminars in Hematology 1992;29:3-12.


  • Erslev AJ.
    Traumatic cardiac hemolytic anemia. Fifth edition.
    Williams Hematology 1995;59:663-665.


  • Erslev AJ.
    March hemoglobinuria and sports anemia. Fifth edition.
    Williams Hematology 1995;61:669-670.


  • Garratty G.
    Immunobiology of Transfusion Medicine.
    Marcel Dekker, Inc., New York, 1994.


  • Gehrs BC, Friedberg RC.
    Autoimmune Hemolytic Anemia.
    Am J Hematology 2002;69:258-271.


  • George JN.
    How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.
    Blood 2000;96:1223-1229.


  • Göttsche B, Salama A, Mueller-Eckhardt C.
    Donath-Landsteiner autoimmune hemolytic anemia in children. A study of 22 cases.
    Vox Sang 1990;58:281-286.


  • Gordjani N, Kretschmer V, Töllner U, Rieger C.
    Foudroyant verlaufende Autoimmunhämolyse vom Kältetyp mit ausgeprägter Vermehrung von monothermischen Kälteagglutininen: Erfolgreiche Therapie mit Membranplasmapherese.
    Monatsschr Kinderheilkd 1990;138:454-456.


  • Habibi B, Homberg J-C, Schaison G, Salmon C.
    Autoimmune Hemolytic Anemia in Children.
    Am J Medicine 1974;56:61-69.


  • Hadnagy CS.
    Agewise distribution of idiopathic cold agglutinin disease.
    Z Gerontol 1993;24:199-201.


  • Indik ZK et al.
    The molecular dissection for Fcg RII receptor mediated phagocytosis.
    Blood 1995;86:4389.


  • Kelton JG.
    Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome: will recent insight into pathogenesis translate into better treatment?
    Transfusion 2002;42:388-392.


  • Kokame K, Matsumoto M, Soejima K et al.
    Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity.
    PNAS 2002;99:11902-11907.


  • Lankford KV, Hillyer CD.
    Thrombotic Thrombocytopenic Purpura: New Insights in Disease Pathogenesis and Therapy.
    Transf Med Reviews 2000;14:244-257.


  • Liszewski MK, Farries TC, Lublin CM, Rooney IA, Atkinson JP.
    Control of the Complement System.
    Advances in Immunology 1996;61:201-283.


  • Luban NLC.
    Review of Neonatal Red Cell Transfusion Practices.
    Blood Transfusion 1994;8:148-153.


  • Mack P, Freedman J.
    Autoimmune Hemolytic Anemia: A History.
    Transf Med Reviews 2000;14:223-233.


  • Martinez J.
    Microangiopathic hemolytic anemia.
    Fifth edition, Williams Hematology 1995;60:665-668.


  • Meletis J, Terpos, E
    Recent insights into the pathophysiology of paroxysmal nocturnal hemoglobinuria.
    Med Sci Monit 2003;9(7):RA161-172.


  • Meyer O, Hackstein H, Hoppe B, Göbel F-J, Bein G, Salama A.
    Fatal immune haemolysis due to a degradation product of ceftriaxone.
    Br J Haematology 1999;105:1-4.


  • Moake JL.
    Thrombotic Micorangiopathies.
    N Engl J Med 2002;347:589-600.


  • Mollision PL, Engelfriet CP, Contreras M.
    Blood Transfusion in Clinical Medicine.
    Tenth edition, Blackwell Science Ltd., 1997


  • Richards A, Goodship JA, Goodship THJ.
    The genetics and pathogenesis of haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura.
    Curr Opin Nephrol Hypertens 2002;11:431-435.


  • Salama A, Ahrens N, Kiesewetter H.
    Serological and Clinical Aspects of Autoimmune Hemolytic Anemias.
    Infus Ther Transfus Med 2002;29:206-217.


  • Salama A, Mueller-Eckhardt C.
    Immune-Mediated Blood Cell Dyscrasias Related to Drugs.
    Seminars in Hematology 1992;29:54-63.


  • Salama A, Mueller-Eckhardt C.
    Autoimmune haemolytic anaemia in childhood associated with non-complement binding IgM autoantibodies.
    Brit J Haemat 1987;65:67-71.


  • Salama A, Mueller-Eckhardt C.
    The role of metabolite-specific antibodies nomifensine-dependent immune hemolytic anemia.
    New Engl J Med 1985;313:469-474.


  • Salama A, Mueller-Eckhardt C.
    Delayed hemolytic transfusion reactions. Evidence for complement activation involving allogeneic and autologous red cells.
    Transfusion 1984;24:188-193.


  • Salama A, Bhakdi S, Mueller-Eckhardt C, Kayser W.
    Deposition of the terminal C5b-9 complement complex on erythrocytes by human red cell autoantibodies.
    Brit J Haemat 1983;55:161-160.


  • Socieé G. Mary JY, de Gramont A, Rio B, Leporrier M, Rose C, Heudier P, Rochant H, Cahn JY, Gluckman E.
    Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors.
    The Lancet 1996;348:573-577.


  • Sokol RJ, Hewitt S, Stamps,BK, Hitchen PA.
    Autoimmune Haemolysis in Childhood and Adolescence.
    Acta haemat 1984;72:245-257.


  • Schreiber AD, Frank MM.
    Role of antibody and complement in the immune clearance and destruction of erythrocytes . I. In vivo effects of IgG and IgM complement-fixing sites.
    J Clin Invest 1972;51:575.


  • Terada K, Tanaka H, Mori et al.
    Hemolytic Anemia Associated with Cold Agglutinin During Chickenpox and a Review of the Literature.
    J Ped Hematology/Oncology 1998;20:194-151.


  • Zecca M, Nobili B, Ramenghi U, Perrotta S.
    Rituximab for the treatment of refractory autoimmune hemolytic anemia in children.
    Blood 2003;101:3857-3861.


  • Zuelzer WW, Mastrangelo R, Stulberg CS.
    Autoimmune Hemolytic Anemia. Natural History and Viral-Immunologic Interactions in Childhood.
    Am J Medicine 1970;49:80-93.


Aktuelle Berichte vom 58th
ASH Annual Meeting 2016,
San Diego, Kalifornien, USA [Mehr]
2016 ASCO Annual Meeting - aktuelle Berichte. Dieser Service wird gefördert durch:
mehr 
[Mehr]